Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2018 08:03 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Initiates Patient Dosing in Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer's Disease

Pittsburgh, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other...
June 05, 2018 08:02 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Initiates NIA-Funded SNAP Study of Elayta™ to Measure Toxic Oligomer Displacement and Clearance in Alzheimer's Disease

Pittsburgh, June 05, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
March 06, 2018 14:04 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at the Annual ASENT Meeting

Pittsburgh, March 06, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
February 12, 2018 09:00 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics to Participate in Leerink Partners 7th Annual Global Healthcare Conference

PITTSBURGH, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment...
January 04, 2018 08:05 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum

Pittsburgh, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
November 04, 2017 10:45 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse Recovery

Pittsburgh, Nov. 04, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
August 23, 2017 09:45 ET | Source: Cognition Therapeutics, Inc.

Function of Cognition Therapeutics’ Neurological Drug Screening Platform Presented at American Chemical Society National Meeting

PITTSBURGH, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
July 31, 2017 08:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics CEO Kenneth I. Moch to Present at Canaccord Genuity Annual Growth Conference

Pittsburgh, July 31, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
July 19, 2017 04:35 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Reports Drug-Drug Interaction Results for CT1812, a Disease-Modifying Alzheimer’s Disease Candidate

PITTSBURGH, July 19, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative small molecule therapeutics for the...